Moreover, ccRCC could be classified into different immune subtypes based on the expression of CENPA and TIMP1. This all suggests that CENPA and TIMP1 are highly promising biomarkers and therapeutic targets. This evidence concerns the gene CENPA and nonpapillary renal cell carcinoma.